Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep;10(7):621-622.
doi: 10.1002/ueg2.12278. Epub 2022 Jul 15.

Ustekinumab in ulcerative colitis- insights from the real-world data

Ido Veisman  1 , Uri Kopylov  1
Affiliations
Editorial

Ustekinumab in ulcerative colitis- insights from the real-world data

Ido Veisman et al. United European Gastroenterol J. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare. Uri Kopylov received speaker and advisory fees from Abbvie BMS Jannsen Takeda Pfizer Sandoz/Novartis Medtronic; and research support from Jannsen Takeda Medtronic.

Comment on

References

    1. Marafini I, Sedda S, Dinallo V, Monteleone G. Inflammatory cytokines: from discoveries to therapies in IBD. Expet Opin Biol Ther. 2019;19(11):1207–17. 10.1080/14712598.2019.1652267 - DOI - PubMed
    1. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti‐interleukin‐12 antibody for active Crohn's disease. N Engl J Med. 2004;351(20):2069–79. 10.1056/nejmoa033402 - DOI - PubMed
    1. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin‐23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin‐17. J Biol Chem. 2003;278(3):1910–14. 10.1074/jbc.m207577200 - DOI - PubMed
    1. Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles‐Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin‐12 and interleukin‐23 for treatment of immune‐mediated disorders. mAbs. 2011;3(6):535–45. 10.4161/mabs.3.6.17815 - DOI - PMC - PubMed
    1. Sands BE, Sandborn WJ, Panaccione R, O’Brien CD, Zhang H, Johanns J, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–14. 10.1056/nejmoa1900750 - DOI - PubMed

MeSH terms